Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)
BACKGRAUND: The widespread prevalence of type 2 diabetes mellitus (T2DM), high mortality and disability of such patients are the reason for the constant active search for effective approaches to hypoglycemic therapy. Recent years have been marked by a change in the strategy for treatment initiation...
Guardado en:
Autores principales: | N. A. Demidov, M. B. Antsiferov, A. V. Zilov |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf000e6cd5f747a181707237cf46b09d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
por: Marina V. Shestakova, et al.
Publicado: (2020) -
Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014) -
EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
por: Gagik Radikovich Galstyan
Publicado: (2013) -
Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010) -
High level of glycated hemoglobin (HbA<sub>1c</sub>) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus
por: M. V. Shestakova, et al.
Publicado: (2021)